Stock Alert: Popular Vehicle & Services, Kaynes Tech, Anant Raj, Man Infra, HCL Tech
Securities in F&O Ban:
Aditya Birla Fashion & Retail (ABFRL), Indian Renewable Energy Development Agency (IREDA), RBL Bank, Hindustan Copper and Chambal Fertilisers & Chemicals shares are banned from F&O trading on 11 June 2025.
Stocks to Watch:
Popular Vehicles and Services received a Letters of Intent (LOI) from Maruti Suzuki India to establish a new independent true value outlet for pre-owned vehicles in Bangalore, Karnataka.
Kaynes Technology Indias wholly owned subsidiary, Kaynes Semicon has entered into an asset purchase agreement with Fujitsu General Electronics (Fujitsu Electronics) to acquire production lines for power modules.
Anant Rajs board approved the re-appointment of Aman Sarin as managing director, chief executive officer (CEO) and chief operating officer (COO) for the five years with effect from 1st January 2026.
Man Infraconstruction agreed to acquire 36.07% stake in its wholly owned subsidiary, Man Realtors and Holdings (MRHPL) at Rs 215 per share. The company holds 63.93% stake in the MRHPL.
HCL Technologies announced an expansion of its partnership with Standard Insurance Company to deliver AI-driven infrastructure and application services to boost efficiency, support rapid growth and enhance customer experience.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
2 hours ago
- Business Standard
Amber to invest ₹6K cr in Noida plant for electronics, appliances
Amber Enterprises is set to invest ₹6,000 crore in a major electronics manufacturing plant near the upcoming Noida International Airport at Jewar. This development was confirmed by Uttar Pradesh's Industrial Development Minister, Nand Gopal Gupta. According to the minister, he met with Amber Enterprises' promoter, Jasbir Singh, in Lucknow recently to discuss the project. The company intends to set up manufacturing units for printed circuit board (PCB) assembly, home appliances and consumer electronics as part of this large-scale initiative. 'This ₹6,000 crore investment will open new avenues of growth and prosperity in the state,' said Gupta, calling the project a key step in Uttar Pradesh's ongoing industrial progress. The Yamuna Expressway Industrial Development Authority (YEIDA) has already issued a Letter of Intent (LoI) for 100 acres of land located in Sector 8, Noida, where the plant will be built. The site is situated close to the Noida International Airport, along the Yamuna Expressway. Government support and future opportunities Minister Gupta highlighted that under Chief Minister Yogi Adityanath's leadership, the state is actively working to attract new investments. 'This (latest investment) will not only accelerate the state's overall development but also create new employment opportunities for the youth,' he said. Amber Enterprises is a well-known manufacturer of air conditioners and related electronics. The planned facility is expected to play a significant role in strengthening the region's electronics and white goods manufacturing ecosystem. Amber Enterprises India Q4 FY25 net profit jumps 22.60 per cent Amber Enterprises India has reported a 22.60 per cent year-on-year rise in consolidated net profit, reaching ₹116.07 crore for the quarter ended March 2025. This is an increase from ₹94.67 crore in the same quarter of the previous year. The company also saw a significant rise in revenue, with sales growing 33.80 per cent to ₹3,753.70 crore, compared to ₹2,805.46 crore in the March 2024 quarter.
India Gazette
4 hours ago
- India Gazette
Indian Pharma Industry is likely to grow at a steady pace of 10% in FY26: Report
New Delhi [India], June 12 (ANI): Pharmaceutical companies in India are expected to grow steadily at a rate of approximately 10 per cent in FY26, driven by price increases and the launch of new products, according to a report by ICICI Securities. The report noted that the revenue growth for the industry was mainly supported by the Rest of the World (RoW) markets. It said 'India biz is likely to grow at a steady pace of approx. 10 per cent in FY26, driven by price increases and new launches'. In contrast, the report stated that the core markets of the United States and India saw a slower pace of growth, recording 6.5 per cent and 10.2 per cent respectively. The performance in the U.S. market remains uncertain, especially due to the looming price competition around generic Revlimid (gRevlimid), which could become a major drag on earnings in the coming year. The report added that export-oriented CDMO (Contract Development and Manufacturing Organisation) companies also showed healthy traction. The report mentioned that companies under coverage delivered a robust performance, reporting 11.2 per cent growth in revenue, 12.6 per cent growth in EBITDA, and 15.2 per cent growth in PAT (Profit After Tax). In Q4FY25, the pharma companies covered in the report posted strong results, with revenue, EBITDA, and PAT growing by 11.7 per cent, 15.6 per cent, and 19.0 per cent respectively. Gross margin saw a slight dip of 10 basis points both year-on-year and quarter-on-quarter, settling at around 67 per cent. However, the EBITDA margin improved by 82 basis points year-on-year to reach 24.9 per cent, although it declined slightly by 12 basis points on a quarterly basis. This margin expansion was supported by operating leverage and cost control measures. The report also highlighted that the aggregate R&D spending of these companies stood at 6.7 per cent of sales in Q4FY25. This was lower compared to 7.2 per cent in Q4FY24, but slightly higher than 6.5 per cent reported in Q3FY25. Overall, ICICI Securities remains optimistic about the Indian pharma sector's performance in FY26, especially supported by domestic market resilience and a strong pipeline of new launches. (ANI)
Business Standard
10 hours ago
- Business Standard
Stock Alert: Sterlite Tech, Zydus Life, Waaree Energies, Tanla Platform
Secutries in F&O Ban: Aditya Birla Fashion & Retail (ABFRL), Central Depository Services (CDSL), Chambal Fertilisers & Chemicals, Hindustan Copper, Indian Energy Exchange (IEX), Indian Renewable Energy Development Agency (IREDA), RBL Bank and Titagrah Rail Systems shares are banned from F&O trading on 11 June 2025. Stocks to Watch: Sterlite Technologies through its demerged business vertical, Global Services Business in consortium with Dilip Buildcon has entered into agreement with Bharat Sanchar Nigam. The agreement pertains to the design, supply, construction, installation, upgradation, operation, and maintenance of the middle-mile network under BharatNet for the Jammu & Kashmir and Ladakh Telecom Circles Package 13. The said contract is valued at Rs 2,631.14 crore. Zydus Lifesciences has received the establishment inspection report (EIR) report from the USFDA for the inspection conducted at its API manufacturing facility located at Ankleshwar. The inspection has been classified as No Action Indicated (NAI). Waaree Energies has signed and executed the power purchase agreement (PPA) with Rewa Ultra Mega Solar (RUMSL) and M.P. Power Management Company (MPPMCL) for the supply of 150 MW Solar power to MPPMCL. Medplus Health Services subsidiary, Optival Health Solutions has received one suspension order for a drug license for store situated at Maharashtra. Tanla Platforms board is scheduled to meet on 16 June 2025, to consider the proposal for buyback of equity shares and other necessary matters. Kaynes Technology Indias board approved the further investment for an amount upto $ 1.03 million towards acquisition of equity shares upto 10,19,802 of Kaynes Holding, wholly owned subsidiary, at an issue price of $1.01 per share.
